GlassScriptPhysician profile
Charles J Wagner
NPI 1366540742
$1,000.58
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $279.99 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $150.23 | 2019-2020 | |
| Genzyme Corporation | $115.71 | 2019-2020 | |
| Csl Behring | $106.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $75.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.06 | 2019 | |
| Bio Products Laboratory USA, INC. | $39.48 | 2019 | |
| Shire North American Group INC | $35.73 | 2019 | |
| Optinose US, INC. | $35.42 | 2019 | |
| Genentech USA, INC. | $27.05 | 2019 | |
| Genentech, INC. | $21.21 | 2019 | |
| Grifols USA, LLC | $21.13 | 2019 | |
| Kaleo, INC. | $20.77 | 2020 | |
| Leo Pharma INC. | $17.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.